NEW YORK – Aperiomics said today that it has closed a $1.8 million Series A financing round to support further development of its metagenomic sequencing technology.
South Carolina-based investment group VentureSouth led a group of investors that also included Pipeline Angels, Propel(x), and high net worth backers in providing the financing.
Aperiomics CEO Crystal Icenhour said in a statement that the new funding will enable it "to make major investments in research and development that will improve [its] technology — making it easier to use and improving access to vital metagenomic information." The company will be able to increase the number of its clinician partners as well as the number of patients it serves, Icenhour said.
The Sterling, Virginia-based firm identifies bacteria, viruses, fungi, and parasites through deep shotgun metagenomic sequencing, machine learning, and a database of 37,000 microorganisms. Its Xplore-Patho test identifies the root cause of infectious diseases and provides insights that healthcare providers can use to prescribe precise treatments for specific conditions, the firm said.
The company recently expanded into a 4,700 square foot facility in Sterling. It anticipates completing the construction of a laboratory there and having it certified in the coming months.